PL373383A1 - Kopozycja medyczna do leczenia stwardnienia tętnic - Google Patents

Kopozycja medyczna do leczenia stwardnienia tętnic

Info

Publication number
PL373383A1
PL373383A1 PL03373383A PL37338303A PL373383A1 PL 373383 A1 PL373383 A1 PL 373383A1 PL 03373383 A PL03373383 A PL 03373383A PL 37338303 A PL37338303 A PL 37338303A PL 373383 A1 PL373383 A1 PL 373383A1
Authority
PL
Poland
Prior art keywords
medicinal composition
treating arteriosclerosis
arteriosclerosis
treating
medicinal
Prior art date
Application number
PL03373383A
Other languages
English (en)
Inventor
Fumitoshi Asai
Toshimori Inaba
Taketoshi Ogawa
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of PL373383A1 publication Critical patent/PL373383A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03373383A 2002-07-18 2003-07-17 Kopozycja medyczna do leczenia stwardnienia tętnic PL373383A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002209165 2002-07-18

Publications (1)

Publication Number Publication Date
PL373383A1 true PL373383A1 (pl) 2005-08-22

Family

ID=30767676

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373383A PL373383A1 (pl) 2002-07-18 2003-07-17 Kopozycja medyczna do leczenia stwardnienia tętnic

Country Status (14)

Country Link
EP (1) EP1555032A1 (pl)
KR (1) KR20050025604A (pl)
CN (1) CN1681533A (pl)
AU (1) AU2003248077A1 (pl)
BR (1) BR0312778A (pl)
CA (1) CA2493384A1 (pl)
IL (1) IL166312A0 (pl)
MX (1) MXPA05000726A (pl)
NO (1) NO20050877L (pl)
PL (1) PL373383A1 (pl)
RU (1) RU2005104432A (pl)
TW (1) TW200407135A (pl)
WO (1) WO2004009119A1 (pl)
ZA (1) ZA200500431B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600497A (en) * 2001-02-02 2006-01-01 Sankyo Co Preparation of indoline derivative
MXPA05014086A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antiagregantes plaquetarios combinadas para su uso en el tratamiento y prevencion de eventos vasculares de origen isquemico.
KR101647842B1 (ko) * 2006-12-07 2016-08-11 다이이찌 산쿄 가부시키가이샤 저장 안정성이 개선된 의약 조성물
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
CN101594864B (zh) * 2006-12-07 2012-04-18 第一三共株式会社 生产固体制剂的方法
WO2008072534A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited マンニトール又は乳糖を含有する固形製剤
CN101594863B (zh) * 2006-12-07 2011-12-07 第一三共株式会社 具有改进稳定性的涂膜制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62167791A (ja) * 1986-01-20 1987-07-24 Morinaga Milk Ind Co Ltd 血小板凝集抑制剤
DK0683789T3 (da) * 1993-02-10 1998-02-09 Astra Pharma Prod N-alkyl-2-substituerede ATP-analoger
CN1097043C (zh) * 1995-10-05 2002-12-25 京都药品工业株式会社 新的杂环衍生物及其医药用途
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
DK1298132T3 (da) * 2000-07-06 2007-03-12 Sankyo Co Hydropyridinderivatsyreadditionssalte

Also Published As

Publication number Publication date
AU2003248077A1 (en) 2004-02-09
CA2493384A1 (en) 2004-01-29
CN1681533A (zh) 2005-10-12
RU2005104432A (ru) 2005-08-10
KR20050025604A (ko) 2005-03-14
BR0312778A (pt) 2005-05-03
EP1555032A1 (en) 2005-07-20
MXPA05000726A (es) 2005-04-08
IL166312A0 (en) 2006-01-15
NO20050877L (no) 2005-02-18
WO2004009119A1 (ja) 2004-01-29
TW200407135A (en) 2004-05-16
ZA200500431B (en) 2006-08-30

Similar Documents

Publication Publication Date Title
GB0221688D0 (en) Compositions for wound treatment
GB2394894B (en) New use for pharmaceutical composition
GB0217225D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
AU2003291103A8 (en) Pharmaceutical composition
IL164547A0 (en) Pharmaceutical composition
AU2003250372A8 (en) Pharmaceutical composition
HUP0401612A3 (en) Pharmaceutical composition suitable for treating diabetes
GB2392618B (en) Compositions for therapeutic use
HUP0600855A3 (en) Androgen pharmaceutical composition for treating depression
HUP0500199A3 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
ZA200500431B (en) Medicinal composition for treating arteriosclerosis
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003252701A1 (en) Medicinal composition for treating thrombopenia
GB0217703D0 (en) Pharmaceutical composition
EP1549327A4 (en) COMPOSITION FOR THE TREATMENT OF HEMORROIDS
EP1547593A4 (en) MEDICINAL COMPOSITION
SI2105135T1 (sl) Farmacevtski sestavki za zdravljenje raka
GB0211355D0 (en) Pharmaceutical composition
GB0228111D0 (en) Pharmaceutical composition
GB0213306D0 (en) Pharmaceutical composition
GB0214491D0 (en) Pharmaceutical composition
GB0220095D0 (en) Pharmaceutical composition
GB0225042D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)